Andreasen N (1989): The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry 155 (suppl. 7):49-52. |
Costa J, Khaled E, Sramek J, Bunney W Jr, Potkin SG (1990): An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics J Clin Psychopharmacol 10:71-72. |
D'Souza DC, Morrissey K, Abi-Saab D, Damon D, Gil R, Bennett A, Krystal JH (1995): Intravenous glycine and oral D-cycloserine effects on CSF amino acids, plasma hormones, and behavior in healthy humans: Implications for schizophrenia. Schiz Res 15:147, 1995. |
Javitt DC and Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308. |
Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994): Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236. |
Johnson JW. Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 325:529-31, 1987. |
Kay SR, Fiszbein, Opler LA (1987): The positive and negative syndrome scale (PANSS) for schizophrenia. Schiz Bull 13:261-276. |
Leiderman Eduardo, Zylberman Ilana, Zukin Stephen R, Cooper Thoms B, Javitt Daniel C. (1996): Preliminary Investigation of High-Dose Oral Glycine on Serum Levels and Negative Symptoms in Schizophrenia: An Open-Label Trial. Biol Psychiatry 39:213-215. |
Potkin SG, Costa Roy S, Sramek J, Jin Y, Gulasekaram B (1992): Glycine in the treatment of schizophrenia--theory and preliminary results, in Novel Antipsychotic Drugs. Edited by Meltzer HY. New York, Raven Press. |
Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG, Deutsch SI (1989): Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmacol 12:416-24. |
Waziri R (1989): Glycine therapy of schizophrenia. Biol Psychiatry 1988, 23:210-211 (letter). |
M. Nilsson, et al., "Glycine and D-serine decrease MK-801-induced hyperactivity inmice" Journal of Neural Transmission (1997) 104: 1195-1205. |
John P. Kaltenbach, et al., "Compounds Protective againsht Renal Tubular necrosis Induced by D-Serine and D-2,3-Diaminoproplonic Acid in the Rat.sup.1 "Experimental and Molecular Pathology 27,225-234 (1982). |
Frank A. Carone, et al., "Urinary Loss of Glucose, Phosphate, and Protein by Diffusion into Proximal Straight Tubules Injured by D-Serine and Maleic Acid" Laboratory Investigation, vol. 52, No. 6, pg. 605, 1985. |
Katsunobu Takahashi, et al., "In Vivo Evidence for the Link Between L-and D-Serine Metabolism in Rat Cerebral Cortex." Journal of Neurochemistry, vol., 69, No. 3, 1997. |
Taka-aki Matsui, et al., "Functional Comparison of D-Serine and Glycine in Rodents: The Effect on Cloned NMDA Receptors and the Extracellular Concentration" Journal of Neurochemistry Vo. 65, No. 1, 1995. |
Guochuan Tsai, et al., "D-Serine Added to Antipsychotics for the Treatment of Schizophrenia" Society of Biological Psychiatry 1998, vol. 44 pg. 1081-1089. |
Toth Eugene, Weiss Benjamine, Banay-Schwartz Miriam, Lajtha Abel (1986): Effect of Glycine Derivatives on Behavioral Changes induced by 3-Mercaptopropionic Acid or Phencyclidine in Mice 11:1-8. |
Ishimaru M, Kurumaji A, Toru M (1994) Increases in strychnine-insensitive glycine binding sites in cerebral cortex . . . evidence for the glutamate hypothesis, Biol. Psychiatry 35:84-95. |
Kretschmer BD, Schmidt WJ (1992), Glycine agonists in the treatmen tof schizophrenia? Clin Neuropharmacol, 15:157-159. |
Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia, Arch. Gen. Psychiatry, 52:998-1007. |
Rosse Rb, Schwartz BL, Davis RE, Deutsch SI (1991), An NMDA intervention strategy in schizophrenia with "low dose" milacemide, Clin Neuropharmacol, 14:268-272. |
Rosse RB, Fay.dbd.McCarthy M, Kendrick K, Davis RE, Deutsch SI (1996), D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia, Clin Neuropharmaol, 19:444-50. |
Waziri R (1996), Glycine therapy of schizophrenia: some caveats, Biol Psyciatry, 39:115-6. |
Wood PL (1995): The co-agonist concept: is the NMDA-associated glycine receptor saturated in vivo? Life Sci 57:301-10. |
Toth et al. (1982): Elevation of Cerebral Levels of Nonessential Amino Acids in vivo by Administration of Large Doses, Neurochemical Research, 6, (12). |